Photo Bio Modulation Treatment

-Simple to use.

-Portable and compact design.

- Laser output begins upon plugging in.

- Compatible with power bank, adapter, or computer power sources.

- Incorporates patented technology protected nationally.

- Clinical trials report around 92% therapeutic efficacy.

- Other wavelengths and power levels are customizable.

- Easily initiate treatment by connecting to power bank; no setup necessary.

Red and near-infrared light therapy has shown effectiveness in the natural treatment of inflammation without the risk of using traditional drugs. In case you have not heard, red light therapy is a safe treatment that uses low-level wavelengths to deeply penetrate the skin and cells. Once the cells are stimulated, it helps reduce oxidative stress and allows the body to generate more energy to support cellular functions. This helps speed up healing, reduce pain and inflammation, and increases body functions.

Red light therapy for pain relief:Dr. Hamblin Michael of Harvard Medical School is among the first Photomedicine researchers in the world.

He has done a lot of research on the effectiveness of Photobiomodulation in pain relief and skincare. In his research, he explains that red light is "a very mild form of stress that activates protective mechanisms in the cells…for instance when longer wavelengths or visibly red light hits the skin, it nudges mitochondria to make energy more efficiently and boost production of healing anti-inflammatories or disease-fighting antioxidants."

Background

Recent studies have underscored the potential of photobiomodulation (PBM) in alleviating neuropathic pain (NP) following spinal cord injury (SCI), suggesting its efficacy in NP relief post-SCI. However, the mechanisms behind this remain unclear. This research aimed to uncover the potential mechanisms by which PBM alleviates NP after SCI.



Methods

We conducted systematic observations and explored the mechanisms of PBM intervention in NP in rats post-SCI. Transcriptome sequencing was utilized to identify CXCL10 as a potential target for PBM intervention, which was then confirmed in rat tissues via reverse transcription-polymerase chain reaction and western blotting. Immunofluorescence co-labeling helped identify astrocytes and microglia as the cells responsible for CXCL10 expression. The involvement of the NF-κB pathway in CXCL10 expression was confirmed using the inhibitor pyrrolidine dithiocarbamate (PDTC) and the agonist phorbol-12-myristate-13-acetate (PMA), further validated through in vivo injection experiments.



Results

Our findings demonstrated that PBM therapy improved NP-related behaviors post-SCI, inhibited the activation of microglia and astrocytes, and reduced CXCL10 expression levels in glial cells, associated with the mediation of the NF-κB signaling pathway. PBM was found to inhibit the activation of the NF-κB pathway and lower downstream CXCL10 expression. The NF-κB pathway inhibitor PDTC had effects similar to PBM in improving pain in SCI animals, while the NF-κB pathway promoter PMA could reverse the beneficial effects of PBM.



Conclusions

Our study offers new insights into the mechanisms by which PBM mitigates NP after SCI. We showed that PBM significantly inhibited the activation of microglia and astrocytes and reduced CXCL10 expression levels. These effects appear to be linked to the NF-κB signaling pathway. Overall, our findings suggest that PBM could be an effective therapy for NP post-SCI, with CXCL10 and NF-κB signaling pathways playing crucial roles in PBM-mediated pain relief after SCI.